Go Pro
NYSE:AVNS

Avanos Medical (AVNS) Stock Price, News & Analysis

Avanos Medical logo
$24.99 0.00 (0.00%)
As of 08/14/2026

About Avanos Medical Stock (NYSE:AVNS)

Advanced

Key Stats

Today's Range
$24.99
$24.99
50-Day Range
$24.79
$25.03
52-Week Range
$9.30
$25.49
Volume
N/A
Average Volume
700,357 shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Reduce

Company Overview

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms. These solutions are intended to help reduce reliance on systemic opioids and support accelerated recovery protocols. The enteral feeding business provides a range of feeding tubes, pumps and accessories to deliver nutrition directly to the gastrointestinal tract, serving patients with swallowing disorders or nutritional deficiencies. In respiratory care, the company’s offerings include patient interfaces, breathing circuits and related disposables that aid in noninvasive ventilation, oxygen therapy and airway management.

Avanos Medical was established as a standalone company in January 2017 following a spin-off from Kimberly-Clark’s healthcare business. Headquartered in Alpharetta, Georgia, the company maintains a presence in key markets across North America, Europe, Asia Pacific and Latin America. Its global sales and distribution network supports hospitals, surgical centers and home healthcare providers with both direct sales teams and distributor partnerships.

Under the leadership of President and Chief Executive Officer Mike Coolbaugh, Avanos pursues a strategy centered on innovation, operational excellence and targeted acquisitions to expand its product portfolio and geographic reach. The company continues to invest in research and development to advance its current offerings and explore new technologies that address evolving clinical needs in pain management, nutritional support and respiratory therapy.

AI Generated. May Contain Errors.

Avanos Medical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

AVNS MarketRank™: 

Avanos Medical scored higher than 12% of companies evaluated by MarketBeat, and ranked 869th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Avanos Medical has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Avanos Medical has only been the subject of 2 research reports in the past 90 days.

  • Read more about Avanos Medical's stock forecast and price target.
  • Earnings Growth

    Earnings for Avanos Medical are expected to decrease by -11.32% in the coming year, from $1.06 to $0.94 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avanos Medical is -15.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avanos Medical is -15.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Avanos Medical has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.83% of the float of Avanos Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    Avanos Medical has a short interest ratio ("days to cover") of 2.35, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avanos Medical has recently decreased by 1.31%, indicating that investor sentiment is improving.
  • Dividend Yield

    Avanos Medical does not currently pay a dividend.

  • Dividend Growth

    Avanos Medical does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Avanos Medical this week, compared to 2 articles on an average week.
  • Search Interest

    6 people have searched for AVNS on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Avanos Medical to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avanos Medical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.33% of the stock of Avanos Medical is held by insiders.

  • Percentage Held by Institutions

    95.17% of the stock of Avanos Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Avanos Medical's insider trading history.
Receive AVNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AVNS Stock News Headlines

Analyzing Curaleaf (OTCMKTS:CURLF) and Avanos Medical (NYSE:AVNS)
Avanos Medical (AVNS) Projected to Release Earnings on Monday
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Headlines

AVNS Stock Analysis - Frequently Asked Questions

Avanos Medical's stock was trading at $11.23 on January 1st, 2026. Since then, AVNS shares have increased by 122.5% and is now trading at $24.99.

Avanos Medical, Inc. (NYSE:AVNS) posted its quarterly earnings data on Tuesday, May, 5th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.16 by $0.06. The company's revenue for the quarter was up 8.8% compared to the same quarter last year.

Top institutional investors of Avanos Medical include BlackRock Inc. (15.94%), Polar Asset Management Partners Inc. (1.60%), Pentwater Capital Management LP (1.60%) and Samson Rock Capital LLP (1.28%). Insiders that own company stock include Michael Greiner, Gary Blackford, Kerr Holbrook and Julie Ann Shimer.
View institutional ownership trends
.

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avanos Medical investors own include JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Home Depot (HD), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

Last Earnings
5/05/2026
Today
8/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Supplies
Current Symbol
NYSE:AVNS
CIK
1606498
Fax
N/A
Employees
2,287
Year Founded
2014

Profitability

EPS (Trailing Twelve Months)
($1.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
23.58
P/E Growth
N/A
Net Income
-$72.90 million
Net Margins
-10.39%
Pretax Margin
-9.54%
Return on Equity
5.39%
Return on Assets
3.97%

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
2.48
Quick Ratio
1.40

Sales & Book Value

Annual Sales
$715.90 million
Price / Sales
1.64
Cash Flow
$3.42 per share
Price / Cash Flow
7.30
Book Value
$16.73 per share
Price / Book
1.49

Miscellaneous

Outstanding Shares
46,848,000
Free Float
45,756,000
Market Cap
$1.17 billion
Optionable
Optionable
Beta
1.57

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NYSE:AVNS) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners